NCT06938139Active, not recruiting
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy
Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy: A Multicentre Analysis
Source: ClinicalTrials.gov · Last updated 22 Apr 2025
Brief summary (registry, in English)
The Benchmark-MISGC study was a large-scale retrospective observational study launched by the China Gastric Cancer Surgical Union, aiming to establish the benchmarks of the short- and long-term outcomes for gastric cancer patients who underwent minimal invasive gastrectomy.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 90000 (estimated)
- First submitted
- 28 Mar 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Fujian Medical University
- NCT number
- NCT06938139
What you commit to
- Study type: Observational
- Planned participants: 90000
- From 1 Mar 2025 to the primary completion date, 30 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Palliative resection;
Other illness
- remnant gastric cancer;
- concurrent/previous malignant disease;
Other
- ASA class \> 3;
- Distant metastasis;
- Abodominal exploration.
Who the study is looking for
- Patients with postoperative histologically confirmed gastric adenocarcinoma at stages T1-4a, N0/+, M0;
- underwent robotic or laparoscopic gastrectomies with curative intent
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Medical University Union Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.